Agile Therapeutics News Releases https://ir.agiletherapeutics.com/ Agile Therapeutics News Releases en Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla® https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-announces-fda-acceptance-nda-resubmission-0 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of November 16, 2019 PRINCETON, N.J. , May 22, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review the Wed, 22 May 2019 07:00:00 -0400 Agile Therapeutics News Releases 9331 Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla® https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-resubmits-new-drug-application-nda-its-0 PRINCETON, N.J. , May 17, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration ( FDA ) the NDA for its lead product candidate, Twirla ® , an investigational low-dose combined Fri, 17 May 2019 07:30:00 -0400 Agile Therapeutics News Releases 9316 Agile Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-present-2019-rbc-capital-markets-global PRINCETON, N.J. , May 09, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari , will present at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 Thu, 09 May 2019 08:00:00 -0400 Agile Therapeutics News Releases 9311 Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-present-combined-safety-data-three-phase-3 PRINCETON, N.J. , May 03, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women's healthcare company, today announced that the combined safety data from three Phase 3 studies of Twirla ® (AG200-15), an investigational, once weekly, low-dose hormonal contraceptive patch, will Fri, 03 May 2019 08:00:00 -0400 Agile Therapeutics News Releases 9291 Agile Therapeutics Reports First Quarter 2019 Financial Results https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-reports-first-quarter-2019-financial-results Company Plans to Resubmit Twirla® NDA in Second Quarter of 2019 Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 PRINCETON, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial Thu, 02 May 2019 16:15:00 -0400 Agile Therapeutics News Releases 9281 Agile Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in London, UK https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-present-hc-wainwright-global-life-sciences PRINCETON, N.J. , March 28, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the H.C. Wainwright Global Life Sciences conference on Monday April 8, 2019 at 3:50 Thu, 28 Mar 2019 08:00:00 -0400 Agile Therapeutics News Releases 9251 Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-present-vivo-adhesion-data-two-phase-1 PRINCETON, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women's healthcare company, today announced that an abstract presenting data from two Phase 1 in vivo wear studies on the adhesion of Twirla ® has been selected for a poster presentation during the 2 Fri, 15 Mar 2019 08:00:00 -0400 Agile Therapeutics News Releases 9226 Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-reports-fourth-quarter-and-full-year-2018 Cash Expected to Enable Company to Fund Operations into the Fourth Quarter of 2019 Company plans to resubmit Twirla NDA in second quarter of 2019 PRINCETON, N.J. , March 12, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial Tue, 12 Mar 2019 16:15:00 -0400 Agile Therapeutics News Releases 9206 Agile Therapeutics to Present at Upcoming Investor Conferences https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-present-upcoming-investor-conferences PRINCETON, N.J. , March 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Senior Vice President and Chief Financial Officer, Scott Coiante will present at Oppenheimer’s 29 th Annual Healthcare Conference on Tuesday March 19, Mon, 11 Mar 2019 04:00:00 -0400 Agile Therapeutics News Releases 9201 Agile Therapeutics Announces $7.8 Million Private Placement https://ir.agiletherapeutics.com/news-releases/news-release-details/agile-therapeutics-announces-78-million-private-placement PRINCETON, N.J. , March 04, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced today that it has entered into a definitive stock purchase agreement with Perceptive Advisors, LLC , for the private placement of approximately 8.4 million shares of Mon, 04 Mar 2019 07:30:00 -0500 Agile Therapeutics News Releases 9181